NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

MDWD

MediWound Ltd

May 09 • 04:00PM ET

17.52

Dollar change +0.07
Percentage change 0.37	%

Healthcare • Biotechnology • Israel • NASD

Peers: AVIR VRCA ABEO CLGN DERM LRMR XCUR MRNS OCGN UBX

| Held by: IWM IZRL IWO VTWO IWC VTWG RSSL UWM URTY VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.07	Insider Own	32.96%	Shs Outstand	10.79M	Perf Week	1.59%
Market Cap	189.41M	Forward P/E	-	EPS next Y	-2.38	Insider Trans	0.00%	Shs Float	7.25M	Perf Month	8.25%
Income	-30.22M	PEG	-	EPS next Q	-0.66	Inst Own	33.22%	Short Float	14.40%	Perf Quarter	-3.34%
Sales	20.22M	P/S	9.37	EPS this Y	5.94%	Inst Trans	-5.22%	Short Ratio	14.93	Perf Half Y	-1.71%
Book/sh	2.89	P/B	6.07	EPS next Y	16.35%	ROA	-43.19%	Short Interest	1.04M	Perf Year	-7.52%
Cash/sh	3.99	P/C	4.39	EPS next 5Y	17.08%	ROE	-96.33%	52W Range	12.78 - 24.00	Perf YTD	-1.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-80.24%	52W High	-26.98%	Beta	0.30
Dividend TTM	-	Quick Ratio	1.86	Sales past 5Y	-6.42%	Gross Margin	13.03%	52W Low	37.13%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	1.97	EPS Y/Y TTM	-300.13%	Oper. Margin	-95.85%	RSI (14)	52.41	Volatility	4.00% 4.47%
Employees	111	Debt/Eq	0.22	Sales Y/Y TTM	8.22%	Profit Margin	-149.46%	Recom	1.00	Target Price	30.00
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	-91.64%	Payout	-	Rel Volume	0.40	Prev Close	17.46
Sales Surprise	1.49%	EPS Surprise	37.50%	Sales Q/Q	9.40%	Earnings	May 21 BMO	Avg Volume	69.95K	Price	17.52
SMA20	0.32%	SMA50	3.02%	SMA200	-0.27%	Trades		Volume	28,295	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-25	Initiated	Alliance Global Partners	Buy	$25
Feb-28-25	Initiated	Craig Hallum	Buy	$39
Jul-16-24	Reiterated	Maxim Group	Buy	$25 → $30
Dec-22-22	Initiated	Maxim Group	Buy	$11
Jul-18-22	Resumed	Oppenheimer	Outperform	$7
Sep-23-20	Initiated	BTIG Research	Buy	$6
Nov-28-16	Initiated	Aegis Capital	Buy	$11
Aug-17-16	Initiated	Wells Fargo	Outperform
Apr-16-14	Initiated	Oppenheimer	Outperform	$25

May-08-25 06:05PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-25 08:00AM	MediWound to Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-28-25 08:00AM	MediWound to Present New EscharEx Data at Leading Wound Care Conferences (GlobeNewswire)
Mar-21-25 06:31PM	MediWound Ltd (MDWD) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Mar-20-25 03:01AM	MediWound Ltd (MDWD) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Losses (GuruFocus.com) -6.73%
12:10PM	Loading…
Mar-19-25 12:10PM	MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.14%
08:10AM	MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:17AM	MediWound: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 08:00AM	MediWound to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 08:00AM	MediWound Announces Phase III CIDS Publication on NexoBrid for Pediatric Burn Care (GlobeNewswire) -7.28%
Feb-24-25 08:00AM	MediWound to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-13-25 10:27AM	MediWound commences Phase III trial for venous leg ulcers treatment (Clinical Trials Arena)
Feb-12-25 07:00AM	MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers (GlobeNewswire)
Feb-04-25 08:00AM	MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
06:32AM	Loading…
Jan-27-25 06:32AM	MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains? (Zacks)
Jan-09-25 08:28AM	Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions (TipRanks)
Dec-17-24 08:00AM	MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025 (GlobeNewswire)
07:27AM	MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Companys Future (TipRanks)
Nov-27-24 02:02AM	MediWound Ltd (MDWD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-26-24 08:15AM	MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:10AM	MediWound: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Nov-25-24 07:02AM	What To Expect From MediWound Ltd (MDWD) Q3 2024 Earnings (GuruFocus.com) +5.16%
Nov-12-24 08:00AM	MediWound to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-23-24 07:01PM	Rosalind Advisors, Inc. Increases Stake in MediWound Ltd (GuruFocus.com)
Oct-10-24 07:00AM	MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx vs. Collagenase in Patients with Venous Leg Ulcers (GlobeNewswire)
Oct-08-24 08:00AM	MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-03-24 08:00AM	MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -7.34%
Aug-16-24 10:33AM	MediWound and Vericel win FDA paediatric label expansion for NexoBrid (Medical Device Network) +6.05%
04:15PM	Loading…
Aug-15-24 04:15PM	MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Aug-14-24 08:15AM	MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:18AM	MediWound: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Aug-07-24 10:00AM	MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Aug-05-24 07:30AM	MediWound Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT) (GlobeNewswire) -6.46%
Aug-02-24 08:00AM	MediWound to Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-31-24 09:55AM	Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-30-24 07:13AM	MediWound reinforces wound therapy EscharEx data ahead of Phase III trial (Medical Device Network)
Jul-29-24 08:00AM	MediWound Announces Publication of the EscharEx Phase II ChronEx Study Results for Venous Leg Ulcers (GlobeNewswire)
Jul-16-24 07:30AM	MediWound Announces 16.25 Million Funding from the European Innovation Council Accelerator Program (GlobeNewswire)
Jul-15-24 07:38AM	Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd (PR Newswire)
07:38AM	Molnlycke Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd (PR Newswire)
07:00AM	MediWound Announces $25 Million Strategic Private Placement Financing (GlobeNewswire)
May-29-24 02:40PM	A burn treatment company's stock has soared amid Israel's war in Gaza (Quartz) -10.01%
11:53AM	MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:15AM	MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:12AM	MediWound: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	MediWound Reports First Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
May-22-24 08:00AM	MediWound to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 08:00AM	MediWound to Present New Data from EscharEx Phase II Studies at Three Leading Wound Care Conferences (GlobeNewswire)
Apr-17-24 07:24AM	Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength? (Zacks)
Mar-25-24 09:55AM	Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High? (Zacks)
08:50AM	What Makes MediWound (MDWD) a Good Fit for 'Trend Investing' (Zacks)
Mar-21-24 11:54AM	MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:25AM	MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:25AM	MediWound: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (GlobeNewswire)
Mar-14-24 08:00AM	MediWound to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-06-24 08:46AM	MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last? (Zacks) +7.52%
Feb-12-24 07:00AM	MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx vs. SANTYL within the ChronEx Phase II Randomized Controlled Study (GlobeNewswire)
Feb-05-24 08:00AM	MediWound to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -8.69%
Jan-15-24 09:55AM	MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Jan-09-24 06:21PM	Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet (Zacks) +5.67%
08:48AM	MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
07:00AM	MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Dec-28-23 07:00AM	MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army (GlobeNewswire)
Dec-21-23 08:00AM	MediWound Announces Peer-Reviewed Publication of EscharEx Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads (GlobeNewswire)
Dec-13-23 09:55AM	Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to Trade (Zacks)
Nov-27-23 09:55AM	Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect? (Zacks)
Nov-21-23 07:12AM	MediWound: Q3 Earnings Snapshot (Associated Press Finance)
07:02AM	MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire)
07:00AM	MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer (GlobeNewswire)
Nov-14-23 08:02AM	MediWound to Report Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-13-23 07:00AM	MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid to Treat Pediatric Patients (GlobeNewswire)
Nov-08-23 07:00AM	MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid Distribution in Europe (GlobeNewswire)
Oct-11-23 06:00AM	MediWound Announces Collaboration with 3M on EscharEx Phase III Study (GlobeNewswire)
Oct-09-23 07:34AM	MediWound Deploys NexoBrid for Emergency Supply (GlobeNewswire)
Oct-03-23 01:20PM	Q4 Stock Predictions: 3 Micro-Cap Stocks Ready to Skyrocket Into 2024 (InvestorPlace)
Sep-29-23 08:00AM	MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains? (Zacks)
Sep-26-23 07:00AM	MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army (GlobeNewswire)
Sep-21-23 06:00AM	MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults (GlobeNewswire)
Sep-11-23 08:00AM	MediWounds NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress (GlobeNewswire) +6.82%
Sep-05-23 08:00AM	MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 05:15PM	MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:11PM	MediWound: Q2 Earnings Snapshot (AP Finance)
04:03PM	MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire)
04:02PM	MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study (GlobeNewswire)
04:01PM	MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study (GlobeNewswire)
Aug-07-23 08:00AM	MediWound to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-01-23 07:30AM	MediWound Announces Commercial Launch of NexoBrid® in Japan (GlobeNewswire)
Jul-11-23 06:05AM	3 Micro-Cap Stocks to Buy for Multibagger Returns (InvestorPlace)
Jul-10-23 07:30AM	MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jul-03-23 07:00AM	MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design (GlobeNewswire)
Jun-28-23 06:51AM	MediWound (NASDAQ:MDWD) shareholders have endured a 79% loss from investing in the stock five years ago (Simply Wall St.)
Jun-14-23 08:00AM	MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023 (GlobeNewswire)
Jun-01-23 06:07AM	Analyst Forecasts Just Became More Bearish On MediWound Ltd. (NASDAQ:MDWD) (Simply Wall St.)
May-30-23 08:15AM	MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.46%
07:08AM	MediWound: Q1 Earnings Snapshot (AP Finance)
07:00AM	MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update (GlobeNewswire)

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDWD

MediWound Ltd

Upgrade your FINVIZ experience